Dr. Raj P. Singh, M.D.
Nephrology (Kidney) (Nephrology Physician)
1294 S Jones Blvd
Las Vegas, NV 89146
Who else practices at this address →
Clark County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 325
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
NV license 12939 -
Internal Medicine Physician
CA license A 104464
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sunrise Hospital and Medical Center Las Vegas, NV
- Summerlin Hospital Medical Center Las Vegas, NV
- University Medical Center Las Vegas, NV
- Valley Hospital Medical Center Las Vegas, NV
Medical groups
- Nephrology and Endocrine Associates Inc (64 clinicians)
- Raj P Singh MD PLLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 325
- Services billed
- 1,200
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 561 | 135 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 193 | 66 |
| Established patient office or other outpatient visit, 30-39 minutes | 86 | 50 |
| Established patient office or other outpatient visit, 40-54 minutes | 56 | 35 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 55 | 50 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 45 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 20 payments worth $455 in total to this clinician.
| Amgen Inc. | $85.21 |
|---|---|
| Gilead Sciences, Inc. | $72.35 |
| Viiv Healthcare Company | $59.78 |
| Antares Pharma, Inc. | $58.68 |
| AbbVie Inc. | $44.32 |
| Novartis Pharmaceuticals Corporation | $39.26 |
| Travere Therapeutics, Inc. | $38.29 |
| Daiichi Sankyo Inc. | $19.50 |
| Food and Beverage | $455 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $541,593 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
AstraZeneca Pharmaceuticals LP - NB (Contrave) Cardiovascular Outcomes Trial
Currax Pharmaceuticals LLC - Roche Cancer Screening Collection Study
Genentech, Inc. - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participan…
AstraZeneca Pharmaceuticals LP - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulm…
AstraZeneca Pharmaceuticals LP - BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chron…
Bayer HealthCare Pharmaceuticals Inc. - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - ISM2512029A-Nasal Swab Collection in Patients Symptomatic or Confirmed Positive of COVID-19, Influenza A, or Influenza B
Abbott Laboratories
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.